Best Life Sciences Platforms and Tools Companies in South Holland, Netherlands
The 39 best Life Sciences Platforms and Tools companies in South Holland, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ncardia.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in South Holland
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ncardia Company offering hiPSC based products and services for drug discovery and development | $77M | 57 mo ago | Series C | 79 | Stefan Braam Co-Founder & President | HubSpot CMS Hubcore-jsjQuery+12 | 35 patents Manufacturing and differentiation of pluripotent stem cell-derived cardiomyocytes | 1 launch |
| 2 | Mimetas Develops microfluidics-based organ-on-a-chip tissue models | $29M | 48 mo ago | Series B | 108 | Paul Vulto Co-Founder & Co-CEO | Webflowcore-jsjQuery+12 | 86 patents Microfluidic organ‑on‑a‑chip platforms for tissue models and high‑throughput assay plates | 1 launch |
| 3 | Amarna Therapeutics Developer of immune-modulating gene therapies for rare and prevalent autoimmune diseases and genetic diseases | $11M | 82 mo ago | Series A | 30 | Marjanne Messie CFO | CMS Made SimplePleskPHP+15 | 5 patents Recombinant protein expression in mammalian cells and polyomavirus vector production | — |
| 4 | ProteoNic Provider of products and services for improving recombinant protein production levels | $8M | 179 mo ago | Series A | 20 | Frank Pieper CEO | WordPressMySQLPHP+23 | — | — |
| 5 | Pepscope Provider of services for proteomics using microarray and mass spectrometry | $5M | 68 mo ago | Deadpooled | — | Jos Joore Co-Founder & CEO | — | — | — |
| 6 | Delmic B.V. Provider of light and electron microscopy solutions for life sciences and materials science | $4M | 41 mo ago | Series A | 50 | Sander Hoedt CEO | HubSpot CMS HubRequireJSLazySizes+19 | 88 patents Focused ion beam micromachining and multi‑beam charged‑particle inspection for semiconductor samples | — |
| 7 | BIOND Solutions Developer of organ-on-chip platform for cell-based assays | $4M | 54 mo ago | Series A | 13 | — | WordPressMySQLPHP+28 | 16 patents Microfluidic 3D muscle tissue chambers and stretchable organ‑on‑chip platforms | — |
| 8 | Harbour Antibodies Production of antibodies and VH (heavy chain with one variable) domains for therapy | $3M | 78 mo ago | Acquired | 10 | — | — | 25 patents Therapeutic antibodies for cancer, viral targets, BBB delivery, and antibody‑nanoparticle conjugates. | — |
| 9 | Toxys Developer of In vitro genotoxicity testing services | $2M | 77 mo ago | Public | 23 | — | WordPressApple iCloud MailMicrosoft 365+42 | 3 patents In vitro embryotoxicity testing of agents using mammalian embryo development assays. | 1 launch |
| 10 | DAB Technology solutions provider for accelerated fermentation | $2M | 10 mo ago | Series A | 20 | Kirsten Herben-Steinbusch Founder | SanityRadix UITailwind CSS+18 | — | — |
| 11 | GenomeScan Provider of next-generation genome sequencing and testing | $1M | 46 mo ago | Funding Raised | 38 | Peter Belt CEO | WordPressMySQLPHP+28 | — | — |
| 12 | BaseClear Contract service laboratory with a focus on DNA technology, genomics and synthetic biology. | $1M | 85 mo ago | Funding Raised | 96 | — | WordPress Block EditorCart FunctionalityWordPress+27 | — | — |
| 13 | Aeon Astron Biotech company focusing on development and marketing of biomaterials and regenerative medical technology for… | $937K | 128 mo ago | Deadpooled | 44 | Michael Lai CEO & Chairman | — | — | — |
| 14 | ViaZym Developer of bioengineered enzymes | $935K | 80 mo ago | Funding Raised | — | Luuk Langen CEO | — | — | — |
| 15 | 20Med Therapeutics Develops RNA-based therapeutics and vaccines for drug delivery | $736K | 39 mo ago | Series A | 13 | Michiel Lodder CEO | — | 15 patents Azanaphthalene-functionalized polymer carriers for gene and drug delivery | — |
| 16 | ZF-Screens Platform for high-throughput screening of pharmaceutical drug candidates against diseases. | $632K | 137 mo ago | Deadpooled | — | Ron Dirks CEO | — | 3 patents High‑throughput in vivo screening platforms for drug discovery and biological assay development. | — |
| 17 | Imuno Therapeutics Developer of drug discovery and precision therapy platform for oncology | $340K | 57 mo ago | Seed | 5 | Jan Verhoef Founder | — | — | — |
| 18 | ZoBio Provider of fragment-based drug discovery services | $278K | 126 mo ago | Acquired | 43 | — | WordPressPleskMySQL+26 | — | 1 launch |
Top 12 Life Sciences Platforms and Tools companies in South Holland
#1
Series A · Delft, South Holland · founded 2012 · 20 employees$2.2Mraised▾
DAB is a technology solutions provider for accelerated fermentation. It enables the production of chemicals, materials, and fuel from renewable feedstock. It also provides solutions for fermentations with a water-insoluble product.
- Oct 2025Series A—
- May 2019Series A$2.2M
#2
Series C · The Hague, South Holland · founded 2011 · 79 employees$77.4Mraised▾
Ncardia, formed by the merger of Pluriomics and Axiogenesis in 2017, is a stem-cell based drug discovery and development services provider specializing in offering hiPSC (human induced Pluripotent Stem Cells) based products and services. Both the companies were providers of human cardiovascular stem cell technology, disease modeling and cell-based assay products and services for cardiovascular drug development at the time of the merger. The company also offers its services for cardiovascular and neural safety and efficacy studies. The company has offices in Belgium, the Netherlands, Germany, and the USA. Their product portfolio includes cardiac cells (hiPSC-derived), cardiac fibroblasts, neural cells (includes pan-neuronal cells, astrocytes and peripheral neurons) and cardiac plates (ready-to-use assay plates).
- Nov 2021Series C$60M
- Feb 2020Grant (prize money)$294.7K
- Jan 2020Grant (prize money)$298K
- Dec 2018Grant (prize money)$3.7M
#3
Series B · Leiden, South Holland · founded 2013 · 108 employees$28.9Mraised▾
Mimetas develops organ-on-a-chip tissue models for evaluating drugs, chemicals, and food components. The products OrganoPlates, OrganoReady, OrganoTEER, and OrganoFlow are microfluidics-based culture plates for in-vitro tissue culture. It enables culturing and screening of 3D organ and tissue models, predicting toxic side effects, drug efficacy, and validates customized disease, toxicology, and transport models.
- Sep 2022Grant (prize money)$272.8K
- Aug 2021Grant (prize money)$59K
- Sep 2020Grant (prize money)$2.2M
- Jun 2020Grant (prize money)$66.9K
#4
Series A · Delft, South Holland · founded 2011 · 50 employees$4.3Mraised▾
Provider of light and electron microscopy solutions for life sciences and materials science. The company claims to have developed a platform for integrated fluorescence and electron microscopy and a cathodoluminescence detection system. It also provides an integrated fluorescence and scanning electron microscope.
- Apr 2023Series A$4.3M
- Nov 2019Grant (prize money)$120K
- Sep 2019Grant (prize money)$2.4M
- Jan 2019Grant (prize money)$14.3K
#5
Series A · Delft, South Holland · founded 2016 · 13 employees$4.3Mraised▾
Developer of organ-on-chip platform for cell-based assays. The company develops Organ-on-Chips (OOCs) to outperform the limitation of standard in vitro assays. The chip is connected to the pump to apply the desired fluids (liquids or gases) in the channel network. The cell culture inside the chip can be monitored with optical and fluorescence microscopy.
#6
Series A · Leiden, South Holland · founded 2008 · 30 employees$11Mraised▾
Developer of immune-modulating gene therapies for rare and prevalent autoimmune diseases and genetic diseases. Its proprietary platform includes SVac which is a viral vector used for the delivery of gene, prophylactic and therapeutic vaccines targeting indications such as allergies, autoimmune diseases, genetic disorders, cancer, and infectious diseases. It can be used for the treatment of AMD, HIV, Hepatitis, multiple sclerosis, and breast cancer.
- Oct 2019Series A$11M
#7
Funding Raised · Leiden, South Holland · founded 2002 · 38 employees$1.2Mraised▾
Provider of next-generation genome sequencing and testing. The company is focusing on NGS genetic testing and diagnostics, exome sequencing, targeted disease panels, and research and development on genetic testing. The company is involved in finding disease causes using Next Generation Sequencing.
- Nov 2022Grant (prize money)$270.8K
- Jan 2020Grant (prize money)$312.9K
- Oct 2019Grant (prize money)$305K
- Jan 2017Grant (prize money)$336K
#8
Series A · South Holland · founded 2011 · 13 employees$735.8Kraised▾
Develops RNA-based therapeutics and vaccines for drug delivery. Its non-viral delivery platform is based on bioresponsive polymers designed for the intracellular delivery of oligonucleotides. The 20Med Nanoparticles are applicable for the delivery of oligonucleotide-based therapeutics. Its nanogel drug delivery platform provides protection of fragile payloads during administration and circulation but allows for a rapid bioresponsive release of that payload as the particles enter the cytosol. The bioresponsive polymeric nanoparticles can be loaded with oligonucleotides ranging from large plasmid DNAs (>12Kb) to small antisense oligos.
- May 2023Series A—
- Sep 2020Grant (prize money)$316.7K
- Nov 2017Seed—
- Jan 2017Grant (prize money)$419.1K
#9
Deadpooled · The Hague, South Holland · founded 2012$5.2Mraised▾
Provider of services for proteomics using microarray and mass spectrometry
#10
Series A · Leiden, South Holland · founded 2007 · 20 employees$8.1Mraised▾
Provider of products and services for improving recombinant protein production levels. Its proprietary UNic technology is used to enhance the translation of messenger RNA (mRNA) by incorporating Translation enhancing elements in the expression vector, resulting in more protein per mRNA. This leads to significantly higher yields and greater manufacturing flexibility, with lower production costs. The company activities focus on industry-relevant fungal, yeast, plant, and mammalian expression hosts, for which it has developed platform-specific products and services. Services include molecular biology, vector construction, cell line, and production strain development.
- Sep 2011Series A$8.1M
#11
Acquired · Rotterdam, South Holland · founded 2006 · 10 employees$3.3Mraised▾
Harbour Antibodies has developed robust mouse platforms that can generate a diverse array of fully human antibodies. Harbour’s technology can be partnered with large pharma and biotech to develop antibody based therapies. The company has developed two types of human immunoglobulin gene transgenic mice: mice that generate “conventional” tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). Both Harbour transgenic mouse lines are now available to licensing partners.
- Mar 2020Grant (prize money)$110.5K
- Jul 2013Series A$3.3M
#12
Public · Leiden, South Holland · founded 2014 · 23 employees$2.3Mraised▾
Toxys is a provider of in vitro genotoxicity testing services. Its proprietary technology ToxTracker detects carcinogenicity and genotoxicity of chemical compounds and drugs in mouse embryonic cell lines. In addition, the company also offers custom testing services and the ToxPlot software for automated data analysis.
- Mar 2020Series A$2.3M
- Feb 2016Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the Netherlands
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 921 Netherlands-affiliated papers.
- Utrecht University91
- Wageningen University & Research90
- Amsterdam University Medical Centers81
- Erasmus MC75
- Leiden University Medical Center73
- Gene6→24
- Genome7→24
- Transcriptome1→15
- Microbiome1→7
- Phenotype1→7
- Disease1→33
- Transcriptome1→13
- Cancer1→11
- Genome2→12
- Epigenetics1→7
- Disease1→23
- Clinical trial1→7
- Microbiome3→9
- Cancer1→7
- Biomarker1→7
Where bioinformatics is researched across Netherlands
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.